Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial

Germán Áñez; Lisa M. Dunkle; Cynthia L. Gay; Karen L. Kotloff; Jeffrey M. Adelglass; Brandon Essink; James D. Campbell; Shane Cloney-Clark; Mingzhu Zhu; Joyce S. Plested; Pavitra Roychoudhury; Alexander L. Greninger; Nita Patel; Alice McGarry; Wayne Woo; Iksung Cho; Gregory M. Glenn; Filip Dubovsky.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22279903

Documentos relacionados

  1. Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
  2. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
  3. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.